Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00078611 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease
A Phase 3 study of Crohn's Disease, sponsored by Biogen.
- Completed
- Registry status
- Phase 3
- Development phase
- 462
- Enrollment target
- 20
- Study locations
NCT00078611 is a Phase 3 study of Crohn's Disease that has completed, run by Biogen. The registered enrollment target is 462 participants, below the 2,410-participant average among 104 other Crohn's Disease trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT00078611, a Phase 3 study of Crohn's Disease, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 462 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this trial is to evaluate natalizumab in individuals with moderately to severely active Crohn's Disease.
Conditions Studied
Interventions
- DRUG natalizumab
Study Locations (20)
California
- Advanced Clinical Research Institute - Anaheim
- Cedars-Sinai Medical Center - Los Angeles
- Digestive Diseases Foundation - Los Angeles
- David Geffen School of Medicine at UCLA, Division of Digestive Diseases - Los Angeles
- Community Clinical Trials - Orange
- UCSF / Mt. Zion IBD Center - San Francisco
- Shared Medical Research Foundation - Tarzana
Florida
- Malcolm Randall VA Medical Center - Gainesville
- Borland Groover Clinic - Jacksonville
- Miami Research Associates, Inc. - Miami
- Waterside Clinical Research Services, Inc. - West Palm Beach
- Shafran Gastroenterology Center - Winterpark
Colorado
- Lynn Institute of the Rockies - Colorado Springs
- Rocky Mountain Gastroenterology - Golden
- Arapahoe Gastroenterology - Littleton
Arizona
- Harmony Clinical Research - Oro Valley
- Advanced Clinical Therapeutics - Tucson
Connecticut
- Center for Medical Research, LLC - Manchester
District of Columbia
- Morowitz, Marion, Laessing, Shocket, Bashir, Steinberg, Salcedo - Washington D.C.
Georgia
- Atlanta Gastroenterology Associates - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 462 participants |
| Start Date | 2004-03 |
| Est. Completion | 2005-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00078611
The ClinicalTrials.gov registry entry for NCT00078611 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 462 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,410-participant average among 104 other Crohn's Disease trials with a reported enrollment target (81% lower). The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 1 intervention - of which natalizumab is the first listed.
NCT00078611 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT00078611 about?
NCT00078611 is a clinical study titled "A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease". The purpose of this trial is to evaluate natalizumab in individuals with moderately to severely active Crohn's Disease.
What is the current status of trial NCT00078611?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 462 participants. The study started on 2004-03. Estimated completion is 2005-03.
What conditions does trial NCT00078611 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT00078611?
The interventions under investigation include: natalizumab (DRUG).
Who is sponsoring clinical trial NCT00078611?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00078611 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RECRUITING · Phase 3
-
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
RECRUITING · Phase 3
-
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
RECRUITING · Phase 3
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
-
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
RECRUITING · Phase 3
-
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.